Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7214678 | 1.00 | KMT2A (0.51) | KMT2AMEN1ALDH1A1L3MBTL1HTT | |
| SCHEMBL7214498 | 0.86 | KMT2A (0.47) | KMT2AMEN1ALDH1A1L3MBTL1HTT | |
| SCHEMBL7214496 | 0.86 | KMT2A (0.47) | KMT2AMEN1ALDH1A1L3MBTL1HTT | |
| SCHEMBL7220859 | 0.80 | SIGMAR1 (0.36) | KMT2AGAA | |
| SCHEMBL7220863 | 0.80 | SIGMAR1 (0.36) | KMT2AGAA | |
| SCHEMBL7213852 | 0.79 | KMT2A (0.39) | KMT2AMEN1GAA | |
| SCHEMBL7214016 | 0.78 | ACKR3 (0.40) | ALDH1A1 | |
| SCHEMBL7214022 | 0.78 | ACKR3 (0.40) | ALDH1A1 | |
| SCHEMBL6731438 | 0.73 | PKM (0.41) | KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL7220238 | 0.72 | CA12 (0.40) | KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534499-B2 | For therapy of autoimmune disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-03-18 | — | — | US | disclosed |
| US-20020077357-A1 | N-substituted-N'-substituted urea derivatives and the use thereof as TNF-alpha production inhibitory agents | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-20 | — | — | US | disclosed |
| EP-1172359-A1 | N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-$g(a) PRODUCTION INHIBITOR | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077357-A1 | N-substituted-N'-substituted urea derivatives and the use thereof as TNF-alpha production inhibitory agents | TNF, NFKBIA, CHUK | KMT2A 4791/4885MEN1 3957/4885ALDH1A1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.